Compare BLZE & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | MDWD |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.8M | 181.1M |
| IPO Year | 2021 | 2013 |
| Metric | BLZE | MDWD |
|---|---|---|
| Price | $15.66 | $14.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $7.60 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 4.5M | 84.7K |
| Earning Date | 05-04-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $145,835,000.00 | N/A |
| Revenue This Year | $10.16 | $48.92 |
| Revenue Next Year | $10.91 | $35.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.27 | N/A |
| 52 Week Low | $3.26 | $13.54 |
| 52 Week High | $16.59 | $21.26 |
| Indicator | BLZE | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 82.62 | 51.16 |
| Support Level | $3.93 | $13.65 |
| Resistance Level | N/A | $14.99 |
| Average True Range (ATR) | 1.21 | 0.53 |
| MACD | 0.68 | 0.17 |
| Stochastic Oscillator | 90.08 | 69.33 |
Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.